Information for providers

Collaborating with you to serve cancer patients

We are honored to partner with physicians throughout the North Bay Area to serve cancer care patients. We are committed to open communication, collaboration and timely follow-up throughout the cancer treatment process.

Referring a Cancer Care Patient

The Martin-O’Neil Cancer Center welcomes physician referrals. Please submit referrals to the Cancer Center by fax at 707-967-5722 or use the online central referral form. Our team will follow-up with your patient promptly.

Referring a Specialty Infusion Patient

The Martin-O’Neil Cancer Center provides infusion therapy services in a supportive environment with the same quality care and compassion provided to all patients. Providers referring patients to the Martin-O’Neil Cancer Center for specialty infusion therapy services may use the form or renewal form below and submit by fax to 707-967-5722.

Referral for Specialty Infusions

Referral for Specialty Infusions – Renewal Request

Open Clinical Trials

The Martin-O’Neil Cancer Center has several trials open to participation for various cancers.


Cancer Type: Solid Tumor, Lymphoma, Multiple Myeloma

  • Trial Name: EAY131 MATCH/Molecular Analysis for Therapy Choice (MATCH)
    Summary: Treatment for Solid Tumors, Lymphoma & MM, that have progressed following at least 1 line of therapy and/or for Whose Disease No Standard Treatment Exists that has been shown to prolong survival
  • Trial Name: ICON/Exact Sciences
    Summary: Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated solid Tumors (Breast, Lung and Prostate cohorts are currently on hold)

Cancer Type: Breast

  • Trial Name: A011202
    Summary: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy
  • Trial Name: Impassion030
    Summary: A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Cancer Type: Lung

  • Trial Name: Alliance A151216
    Summary: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) - A Screening Trial for A081105 and E4512. For Suspected Non-Squamous Stage IB or II Lung Adenocarcinoma. A081105: Randomized Study of Erlotinib vs Observation in Patients wth Completely Resected Eppidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer TEMPORARY SUSPENSION. E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
  • Trial Name: LUNGMAP
    Summary: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Cancer Type: Cervical

  • Trial Name: RTOG 0724
    Summary: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy


Learn more about our clinical trials program by contacting clinical trials coordinator Jennifer DeBattista at (707) 967-5721 or DeBattJL@ah.org.

Join us for Tumor Board

Physicians and providers are invited to join us for our virtual tumor board meetings each Wednesday from 7:30 – 8:30 a.m. Please contact Shalese Canby at 707-967-5831 or canbysr@ah.org to learn more about this opportunity for education and collaboration.

More Information

Find information on how to refer patients for other services, login to the internal intranet, request practice support and attend education/opportunities at our physicians site.